" />
English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 14 May 2015, 10:27 HKT/SGT
Share:
    

Source: Luye Pharma Group Ltd
Luye Pharma was Selected as a Constituent of The MSCI Global Standard Indexes- China Index
The Company's Competitiveness in Global Capital Market is Highly Recognized

HONG KONG, May 14, 2015 - (ACN Newswire) - A leading innovative pharmaceutical company with strong R&D capability and global vision in China market-Luye Pharma Group Ltd. (stock code: 2186.HK), is pleased to announce that the Group has been selected as a constituent of Morgan Stanley Capital International ("MSCI") China Index under MSCI Global Standard Indexes and will take effect as of market close on 29 May 2015.

Morgan Stanley Capital International ("MSCI") is a leading provider of global equity indices and benchmark-related products and services to investors worldwide. MSCI indices have become the most widely used international equity benchmarks by institutional investors. As one of the key investment benchmarks of the capital market in China, the importance of MSCI Global Standard Indexes - China Index is widely acknowledged. The constituent stocks of the index are companies with outstanding operational performance and long-term growth potential. Nine securities including Luye will be added to and 4 securities will be deleted from the MSCI China Index.

Mr. LIU Dianbo, Executive Chairman and Chief Executive Officer of Luye Pharma Group Ltd. said, "We are honored to become a constituent stock of the MSCI Global Standard Indexes - China Index. This reflects the recognition from global capital market on the Group's operational performance and business potential, and it demonstrates clearly our strong R&D capabilities and attractive product pipeline. Looking forward, upholding the spirit of innovation and the mission of going global, we endeavor to become a leading global pharmaceutical company. Moreover, we will proactively seize market opportunities, strengthen existing business and increase our market share, and therefore maintain our industry leadership to reward the trust of our investors and to maximize the returns to shareholders."



Topic: Press release summary
Source: Luye Pharma Group Ltd

Sectors: Daily Finance, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Luye Pharma Group Ltd Related News
Feb 26, 2020 14:00 HKT/SGT
Oxford Medical Case shows Chiropractics can ease Dizziness and Neck Pain
Feb 11, 2020 15:30 HKT/SGT
Novel approach from Synergy Pharmaceuticals may hold cure to herpes virus
Dec 2, 2019 08:01 HKT/SGT
精準狠!收購博安生物,綠葉製藥劍指千億美元生物藥市場
Dec 2, 2019 08:00 HKT/SGT
精准狠! 收购博安生物,绿叶制药剑指千亿美元生物药市场
Mar 27, 2018 19:54 HKT/SGT
绿叶制药集团有限公司公布2017年全年业绩
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575